Loading...
VBLT logo

Vascular Biogenics Ltd.NasdaqCM:VBLT Stock Report

Market Cap US$12.1m
Share Price
n/a
1Y9.2%
7D-34.5%
1D-8.8%
Portfolio Value
​
View

Vascular Biogenics Ltd.

NasdaqCM:VBLT Stock Report

Market Cap: US$12.1m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Vascular Biogenics (VBLT) Stock Overview

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. More details

VBLT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 14.9% per year over past 5 years

Makes less than USD$1m in revenue ($481K)

Does not have a meaningful market cap ($12M)

Shareholders have been diluted in the past year

+ 1 more risk

VBLT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW482,450 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
482,450 investors already sharing narratives
View all narratives

Vascular Biogenics Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vascular Biogenics
Historical stock prices
Current Share PriceUS$0.16
52 Week HighUS$0.32
52 Week LowUS$0.10
Beta0.71
1 Month Change-33.33%
3 Month Change-45.07%
1 Year Change9.17%
3 Year Change-86.55%
5 Year Change-88.53%
Change since IPO-97.33%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 01

VBL Therapeutics receives non-compliance letter from Nasdaq

VBL Therapeutics (NASDAQ:VBLT) said it had received a written notification from the Nasdaq Stock Market, notifying the company that it is not in compliance with the minimum bid price requirement. The company said the closing bid price of the VBL’s ordinary shares for the 30 consecutive business days from July 20, 2022, to August 30, was less that $1 per share, therefore it no longer meets the minimum bid price requirement. VBL has been provided 180 calendar days, or until February 27, 2023, to regain compliance with Nasdaq. To regain compliance, VBL’s ordinary shares must have a closing bid price of at least $1 for a minimum of 10 consecutive business days.
Seeking Alpha • Aug 15

VBL Therapeutics GAAP EPS of -$0.12

VBL Therapeutics press release (NASDAQ:VBLT): Q2 GAAP EPS of -$0.12. At June 30, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $34.5 million. VBL expects that its cash, cash equivalents, short-term bank deposits, and restricted bank deposits will be sufficient to fund currently planned operating expenses and capital expenditures for at least the next 12 months.
Seeking Alpha • Jul 19

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

VBL Therapeutics (NASDAQ:VBLT) on Tuesday said its phase 3 trial of its ovarian cancer treatment ofra-vec did not meet its main goals. The late-stage trial, called OVAL, did not meet the primary endpoints of achieving a statistically significant improvement in progression-free survival or overall survival. "Based on this outcome, we plan to discontinue the OVAL trial and will review the data from our ongoing Phase 2 trials in metastatic colorectal cancer and recurrent glioblastoma multiforme to determine next steps with the ofra-vec program," said VBLT CEO Dror Harats. The OVAL trial was evaluating a combination of VBLT's ofra-vec with chemotherapy drug paclitaxel vs. a combination of a placebo with paclitaxel in 409 patients with platinum-resistant ovarian cancer. VBLT anticipates that its current cash on hand will be sufficient to fund planned operations for at least the next 12 months.
Analysis Article • May 18

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Sep 03

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Vascular Biogenics recently resumed dosing American patients in its OVAL Phase 3 trial. Trial enrollment should complete in 1H 2022. If the data is positive, the stock price should jump considerably.
Analysis Article • Mar 17

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Analysis Article • Jan 28

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

A look at the shareholders of Vascular Biogenics Ltd. ( NASDAQ:VBLT ) can tell us which group is most powerful...
Analysis Article • Dec 24

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Nov 19

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

It's been a good week for Vascular Biogenics Ltd. (NASDAQ:VBLT) shareholders, because the company has just released...

Shareholder Returns

VBLTUS BiotechsUS Market
7D-34.5%-3.5%0.8%
1Y9.2%32.8%20.5%

Return vs Industry: VBLT exceeded the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: VBLT underperformed the US Market which returned 14.1% over the past year.

Price Volatility

Is VBLT's price volatile compared to industry and market?
VBLT volatility
VBLT Average Weekly Movement13.5%
Biotechs Industry Average Movement10.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: VBLT's share price has been volatile over the past 3 months.

Volatility Over Time: VBLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20007Dror Haratswww.vblrx.com

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd.

Vascular Biogenics Ltd. Fundamentals Summary

How do Vascular Biogenics's earnings and revenue compare to its market cap?
VBLT fundamental statistics
Market capUS$12.11m
Earnings (TTM)-US$15.95m
Revenue (TTM)US$481.00k
25.2x
P/S Ratio
-0.8x
P/E Ratio

Is VBLT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VBLT income statement (TTM)
RevenueUS$481.00k
Cost of RevenueUS$17.00k
Gross ProfitUS$464.00k
Other ExpensesUS$16.42m
Earnings-US$15.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.21
Gross Margin96.47%
Net Profit Margin-3,317.05%
Debt/Equity Ratio0%

How did VBLT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/17 02:22
End of Day Share Price 2023/10/16 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vascular Biogenics Ltd. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gbolahan Amusa BenzChardan Capital Markets, LLC
Michael KingCitizens JMP Securities, LLC
Alethia YoungDeutsche Bank